PCLO and diffuse large B-cell lymphoma: Furthermore, we found that the mutation frequency of TNFAIP3 in PCLO mutated DLBCL patients was significantly higher than that of DLBCL patients without PCLO mutations [1.6% (2/125) vs. 13.6% (6/44)].